Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation
Milica Vukmanovic-Stejic, Emma S Chambers, Mayte Suárez-Fariñas, Daisy Sandhu, Judilyn Fuentes-Duculan, Neil Patel, Elaine Agius, Katie E Lacy, Carolin T Turner, Anis Larbi, Veronique Birault, Mahdad Noursadeghi, Neil A Mabbott, Malcolm H A Rustin, James G Krueger, Arne N Akbar, Milica Vukmanovic-Stejic, Emma S Chambers, Mayte Suárez-Fariñas, Daisy Sandhu, Judilyn Fuentes-Duculan, Neil Patel, Elaine Agius, Katie E Lacy, Carolin T Turner, Anis Larbi, Veronique Birault, Mahdad Noursadeghi, Neil A Mabbott, Malcolm H A Rustin, James G Krueger, Arne N Akbar
Abstract
Background: Immunity decreases with age, which leads to reactivation of varicella zoster virus (VZV). In human subjects age-associated immune changes are usually measured in blood leukocytes; however, this might not reflect alterations in tissue-specific immunity.
Objectives: We used a VZV antigen challenge system in the skin to investigate changes in tissue-specific mechanisms involved in the decreased response to this virus during aging.
Methods: We assessed cutaneous immunity based on the extent of erythema and induration after intradermal VZV antigen injection. We also performed immune histology and transcriptomic analyses on skin biopsy specimens taken from the challenge site in young (<40 years) and old (>65 years) subjects.
Results: Old human subjects exhibited decreased erythema and induration, CD4+ and CD8+ T-cell infiltration, and attenuated global gene activation at the site of cutaneous VZV antigen challenge compared with young subjects. This was associated with increased sterile inflammation in the skin in the same subjects related to p38 mitogen-activated protein kinase-related proinflammatory cytokine production (P < .0007). We inhibited systemic inflammation in old subjects by means of pretreatment with an oral small-molecule p38 mitogen-activated protein kinase inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United Kingdom), which reduced both serum C-reactive protein levels and peripheral blood monocyte secretion of IL-6 and TNF-α. In contrast, cutaneous responses to VZV antigen challenge were increased significantly in the same subjects (P < .0003).
Conclusion: Excessive inflammation in the skin early after antigen challenge retards antigen-specific immunity. However, this can be reversed by inhibition of inflammatory cytokine production that can be used to promote vaccine efficacy and the treatment of infections and malignancy during aging.
Keywords: Aging; inflammation; p38 mitogen-activated protein kinase; varicella zoster virus.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect Dis. 2002;2:659–666.
- Diffey B.L., Langtry J.A. Skin cancer incidence and the ageing population. Br J Dermatol. 2005;153:679–680.
- Bouree P. Immunity and immunization in elderly. Pathol Biol (Paris) 2003;51:581–585.
- Agius E., Lacy K.E., Vukmanovic-Stejic M., Jagger A.L., Papageorgiou A.P., Hall S. Decreased TNF-{alpha} synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med. 2009;206:1929–1940.
- Reed J.R., Vukmanovic-Stejic M., Fletcher J.M., Soares M.V., Cook J.E., Orteu C.H. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med. 2004;199:1433–1443.
- Vukmanovic-Stejic M., Sandhu D., Sobande T.O., Agius E., Lacy K.E., Riddell N. Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans. J Immunol. 2013;190:977–986.
- Oxman M.N. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109(suppl):S13–S17.
- Levin M.J. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494–500.
- Abendroth A., Arvin A.M. Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol. 2001;13:27–39.
- Vossen M.T., Biezeveld M.H., de Jong M.D., Gent M.R., Baars P.A., von Rosenstiel I.A. Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J Infect Dis. 2005;191:198–206.
- Vukmanovic-Stejic M., Sandhu D., Seidel J.A., Patel N., Sobande T.O., Agius E. The characterization of varicella zoster virus-specific T cells in skin and blood during aging. J Invest Dermatol. 2015;135:1752–1762.
- Franceschi C., Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(suppl):S4–S9.
- Furman D., Chang J., Lartigue L., Bolen C.R., Haddad F., Gaudilliere B. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med. 2017;23:174–184.
- Akbar A.N., Reed J.R., Lacy K.E., Jackson S.E., Vukmanovic-Stejic M., Rustin M.H. Investigation of the cutaneous response to recall antigen in humans in vivo. Clin Exp Immunol. 2013;173:163–172.
- Watz H., Barnacle H., Hartley B.F., Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:63–72.
- Lomas D.A., Lipson D.A., Miller B.E., Willits L., Keene O., Barnacle H. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2012;52:416–424.
- Fehr S., Unger A., Schaeffeler E., Herrmann S., Laufer S., Schwab M. Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-α in whole blood and primary cells from different species. Cell Physiol Biochem. 2015;36:2237–2249.
- Vukmanovic-Stejic M., Agius E., Booth N., Dunne P.J., Lacy K.E., Reed J.R. The kinetics of CD4Foxp3 T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest. 2008;118:3639–3650.
- Mabbott N.A., Baillie J.K., Brown H., Freeman T.C., Hume D.A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics. 2013;14:632.
- Watanabe R., Gehad A., Yang C., Scott L.L., Teague J.E., Schlapbach C. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7:279ra39.
- Thome J.J., Farber D.L. Emerging concepts in tissue-resident T cells: lessons from humans. Trends Immunol. 2015;36:428–435.
- Natsuaki Y., Egawa G., Nakamizo S., Ono S., Hanakawa S., Okada T. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat Immunol. 2014;15:1064–1069.
- McGovern N., Schlitzer A., Gunawan M., Jardine L., Shin A., Poyner E. Human dermal CD14(+) cells are a transient population of monocyte-derived macrophages. Immunity. 2014;41:465–477.
- Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746.
- Kumar S., Boehm J., Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717–726.
- Moesgaard F., Lykkegaard N.M., Norgaard L.P., Christophersen S., Mosbech H. Cell-mediated immunity assessed by skin testing (Multitest). I. Normal values in healthy Danish adults. Allergy. 1987;42:591–596.
- Marrie T.J., Johnson S., Durant H. Cell-mediated immunity of healthy adult Nova Scotians in various age groups compared with nursing home and hospitalized senior citizens. J Allergy Clin Immunol. 1988;81:836–843.
- Sadaoka K., Okamoto S., Gomi Y., Tanimoto T., Ishikawa T., Yoshikawa T. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis. 2008;198:1327–1333.
- Laube S. Skin infections and ageing. Ageing Res Rev. 2004;3:69–89.
- Pence B.D., Lowder T.W., Keylock K.T., Vieira Potter V.J., Cook M.D., McAuley E. Relationship between systemic inflammation and delayed-type hypersensitivity response to candida antigen in older adults. PLoS One. 2012;7:e36403.
- Parmigiani A., Alcaide M.L., Freguja R., Pallikkuth S., Frasca D., Fischl M.A. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One. 2013;8:e79816.
- Muyanja E., Ssemaganda A., Ngauv P., Cubas R., Perrin H., Srinivasan D. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest. 2014;124:1.
- Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466:973–977.
- Fourati S., Cristescu R., Loboda A., Talla A., Filali A., Railkar R. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun. 2016;7:10369.
- Watanabe R., Shirai T., Namkoong H., Zhang H., Berry G.J., Wallis B.B. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725–2738.
- Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340:202–207.
- Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340:207–211.
- Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013;496:513–517.
- Hernandez A.L., Kitz A., Wu C., Lowther D.E., Rodriguez D.M., Vudattu N. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest. 2015;125:4212–4222.
- Zhang W.C., Zheng X.J., Du L.J., Sun J.Y., Shen Z.X., Shi C. High salt primes a specific activation state of macrophages, M(Na) Cell Res. 2015;25:893–910.
- Min B., Fairchild R.L. Over-salting ruins the balance of the immune menu. J Clin Invest. 2015;125:4002–4004.
- Patterson H., Nibbs R., McInnes I., Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol. 2014;176:1–10.
- Sweeney S.E. Therapy: the as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev Rheumatol. 2009;5:475–477.
- Di Mitri D., Azevedo R.I., Henson S.M., Libri V., Riddell N.E., Macaulay R. Reversible senescence in human CD4+CD45RA+ J Immunol. 2011;187:2093–2100.
- Lanna A., Henson S.M., Escors D. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat Immunol. 2014;15:965–972.
- Lanna A., Gomes D.C., Muller-Durovic B., McDonnell T., Escors D., Gilroy D.W. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. Nat Immunol. 2017;18:354–363.
- Dominguez A., Godoy P., Torner N. The effectiveness of influenza vaccination in different groups. Expert Rev Vaccines. 2016:1–14.
- Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444.
Source: PubMed